The rate of growth of health spending remains moderate. One area where prices appear to be increasing faster than they have in the past few years is brand-name prescription drugs. Specialized drugs for smaller patient populations have been launched with high nominal prices. Reducing prices of specialty drugs requires improving the productivity of R&D.

BING NEWS:
  • Big Pharma Q1 earnings roundup: Novo, Moderna and Regeneron report
    Building on the continued momentum behind its GLP-1 drugs, the pharma company’s parent company, Novo Holdings, announced a deal in early February to buy contract drug manufacturer Catalent in a deal ...
    05/2/2024 - 4:54 am | View Link
  • Pharma R&D ROI bounced back in 2023 after record low in 2022
    Pharma ROI for research and development rose 4.1% in 2023 compared to a record low of 1.2% in 2022. Pharma’s return on investment (ROI) for research and development (R&D) is seeing a comeback after a ...
    04/29/2024 - 5:20 am | View Link
  • Pharma R&D ROI Spikes in 2023 as ‘Breakthroughs’ Re-Energize Industry: Report
    After a record low in 2022, the pharma industry in 2023 saw a surprise rebound in productivity following one of its slowest years on record, according to a report from audit firm Deloitte.
    04/29/2024 - 2:06 am | View Link
  • Big Pharma's ROI for drug R&D saw 'welcome' rebound in 2023: report
    Eagle-eyed watchers of Deloitte’s annual reports on Big Pharma will have noticed a depressing trend—ever-increasing costs for developing drugs over the past decade as the return on investment sinks | ...
    04/24/2024 - 5:01 pm | View Link
  • More

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News